---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-228639"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-11T00:06:16.638537+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon announces dual WEE1/PKMYT1 inhibitor ACR-2316; plans IND by Q4 2024

## Summary
- ACR-2316 is a novel dual WEE1/PKMYT1 inhibitor designed using Acrivon’s AP3 precision proteomics platform.
- Preclinical studies show single-digit nM IC50 potency and potent single-agent anti-tumor activity in vitro and in vivo.
- IND-enabling studies underway; IND submission targeted for Q4 2024 to initiate monotherapy development.
- Updated corporate presentation confirms cash and marketable securities as of June 30, 2023, with cash runway into 2025.
- Company prioritizes ACR-2316 based on preclinical profile for OncoSignature-based patient selection.

## SEC filing metadata
- accession: 0001193125-23-228639
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523228639/0001193125-23-228639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523228639/d479176d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-228639
- JSON: https://secwatch.observer/filing/0001193125-23-228639.json
- Plain text: https://secwatch.observer/filing/0001193125-23-228639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.